Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Chemotherapy in NSCLC with Brain Metastases
NCT04967417Phase 2Completed
- Sponsor
- Samsung Medical Center
- Start
- May 2022
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Samsung Medical Center. Started May 2022; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04967417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04967417.